FDA Greenlights Tempus AI's Heart Disease Detector as Wall Street Wrestles With 72-Point Valuation Gap

FDA Greenlights Tempus AI's Heart Disease Detector as Wall Street Wrestles With 72-Point Valuation Gap | Health AI Central | Health AI Central